Discover how AI-designed small molecule drugs are reshaping drug discovery. Learn how deep learning, generative models, and structure-based machine learning accelerate target-specific molecule design, optimize ADMET, and compress early discovery timelines from years to months.
Learn what AI-designed small molecule drugs are and how machine learning, deep learning, and generative models are revolutionizing small molecule discovery by exploring chemical space, optimizing ADMET, and accelerating R&D timelines.
Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Learn what PROTACs (proteolysis-targeting chimeras) are, how they work via the ubiquitin–proteasome system, and why protein degraders can outperform traditional small molecule inhibitors in oncology and beyond.
Learn how PROTACs (Proteolysis Targeting Chimeras) and targeted protein degraders are transforming small molecule drug design by eliminating disease-causing proteins, enabling catalytic, durable pharmacology across oncology, immunology, and other therapeutic areas.
Discover how oral small molecule GLP‑1 receptor agonists could replace weekly injections like semaglutide and tirzepatide, offering scalable, room‑temperature‑stable pills that transform obesity and type 2 diabetes care worldwide.
Learn how targeted protein degradation (TPD) uses PROTACs and molecular glue degraders to hijack the ubiquitin–proteasome system, eliminate disease-causing proteins, and expand the “druggable” proteome beyond traditional small molecule inhibitors.
Learn what AI-designed small molecule drugs are and how AI and machine learning are revolutionizing oral drug discovery, from de novo molecular design and multi-parameter optimization to faster, safer clinical candidates.
Learn how targeted protein degraders, especially PROTACs, are transforming small molecule drug discovery by degrading disease‑driving proteins, expanding druggable targets beyond classical enzyme and receptor inhibition.
Discover how oral small molecule GLP‑1 receptor agonists are transforming obesity and type 2 diabetes treatment by replacing injections with once‑daily pills, offering injectable‑level efficacy, easier access, and improved patient adherence.
- 1
- 2